Kieran O’Kane, Chief Commercial Officer of Biodesix Inc. (NASDAQ: BDSX), sold 535 shares of the company’s common stock on February 23, 2026, for a total of approximately $6,834, according to a Form 4 filing with the Securities and Exchange Commission.
The sale was executed at a weighted average price of $12.7756 per share, with transacted prices reported in the range of $12.58 to $13.16. The Form 4 indicates the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs).
Separately, O’Kane exercised options to acquire 1,469 shares of Biodesix common stock on February 20, 2026. Those shares were obtained through the vesting of 1,469 restricted stock units, each described as a contingent right to receive one share of common stock upon vesting.
Following the exercise and the subsequent sale to cover taxes, O’Kane is reported to directly own 9,819 shares of Biodesix.
The insider activity occurred as Biodesix shares were trading at $12.77. Market performance through the year-to-date period shows the stock up 87.79%, and analysis available via InvestingPro notes the shares have produced strong returns over the last three months.
InvestingPro’s commentary also highlights that the company is quickly burning through cash and remains unprofitable. Investors are directed to Biodesix’s Pro Research Report on InvestingPro, which is listed among more than 1,400 US equity reports and accompanied by additional ProTips.
In company financial updates, Biodesix announced preliminary fourth-quarter and full-year 2025 results that exceeded both analyst expectations and the company’s own guidance. The company reported preliminary full-year revenue of $88.5 million, representing a 24% increase from the prior year and surpassing a raised guidance range of $84 million to $86 million.
Management also reported that Biodesix achieved EBITDA profitability for the full year. Fourth-quarter revenue was preliminarily reported at $28.8 million, a 41% year-over-year increase that materially contributed to the annual results.
These reported items collectively indicate a stronger financial profile for Biodesix in 2025, while the contemporaneous InvestingPro analysis underscores ongoing cash consumption and an overall unprofitable status on the metrics it references.